Ovid Therapeutics Shares Slide Premarket After Takeda's Soticlestat Setback
By Colin Kellaher
Shares of Ovid Therapeutics plunged more than 65% in premarket trading Monday following the late-stage failure of Takeda Pharmaceutical's epilepsy drug candidate soticlestat, in which Ovid holds significant financial interest.
Takeda on Monday said soticlestat, which Ovid co-developed through Phase 2, missed its primary endpoints in a pair of Phase 3 studies in the rare epilipsies Dravet syndrome and Lennox-Gastaut syndrome.
Ovid sold its soticlestat rights to Takeda in 2021 for an initial $196 million and remains eligible for up to $660 million in potential regulatory and commercial milestone payments, along with royalties on sales of the drug.
Ovid last year sold a 13% stake in its potential royalty, regulatory and commercial milestone payments to Ligand Pharmaceuticals for $30 million in a deal that extended the New York biopharmaceutical company's cash runway into the first half of 2026.
Ovid on Monday said its R&D and financial strategy is independent of soticlestat's outcome, and that it plans to prioritize and pursue its clinical programs with financial discipline.
The company said it will update its guidance on potential milestones and royalty payments related to soticlestat after Takeda determines how it will proceed on the drug.
Ovid shares, which closed Friday at $3.29, were recently down 66% at $1.11 in premarket trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 17, 2024 09:34 ET (13:34 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks